Vor Biopharma
Most recent annual filing: 2026-03-15
- telitacicept Ph3 topline1H 2027telitacicept Ph3 topline, 1H 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
Discontinued (4)
- tremtelectogene empogeditemcel — Acute Myeloid Leukemia · winddown of prior clinical and manufacturing operations announced May 8, 2025; IP sold in August/September 2025
- tremtelectogene empogeditemcel — Myelodysplastic Syndrome · winddown of prior clinical and manufacturing operations announced May 8, 2025; IP sold in August/September 2025
- VCAR33 — Acute Myeloid Leukemia · winddown of prior clinical and manufacturing operations announced May 8, 2025; IP sold in August/September 2025
- VADC45 — undisclosed · winddown of prior clinical and manufacturing operations; IP sold in August/September 2025
Biotech Distilled coverage (7)
- 2026-08-12 UPDATE: Vor Bio (VOR) - They Sold Into the Rip 🔒 Paid
- 2026-07-21 UPDATE: Vor Bio (VOR) - RA Answers the Watch Item 🔒 Paid
- 2026-07-07 UPDATE: Vor Bio (VOR) - The Anchor Leaves, the Closer Arrives 🔒 Paid
- 2026-06-08 UPDATE: Vor Bio (VOR) - The Free Look Pays Off Twice
- 2026-05-15 UPDATE: Vor Bio (VOR) - NEJM Stamps the Free Look 🔒 Paid
- 2026-04-27 UPDATE: Vor Bio (VOR) - The Anchor is Selling 🔒 Paid
- 2026-04-06 Vor Bio (VOR) - Scientific Deep Dive Fortelitacicept and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.